Mineralys Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting a nine-month net loss of $337.7 million and total assets of $630.1 million.
Key Highlights
- Nine-month net loss: The company reported a net loss of $337,738 thousand for the nine months ended September 30, 2026, compared to $122,417 thousand for the same period in 2025.
- Third-quarter net loss: Net loss for the three months ended September 30, 2026 was $57,328 thousand, versus $36,932 thousand in the prior-year quarter.
- Cash and investments: As of September 30, 2026, cash and cash equivalents were $101,273 thousand and investments were $523,399 thousand, for combined liquid assets of approximately $624.7 million.
- Senior secured term loan: The company carried a senior secured term loan with a current portion of $25,000 thousand and a long-term net portion of $73,273 thousand as of September 30, 2026, a balance not present at December 31, 2025.
- License agreement upfront payment: The cash flow statement reflects an upfront payment of $200,000 thousand pursuant to the Fourth Amendment to License Agreement during the nine months ended September 30, 2026.
- Shares outstanding: As of October 29, 2026, there were 88,557,097 shares of common stock outstanding.
- Public offering: During the second quarter of 2026, the company completed a public offering of 5,660,378 shares, raising net proceeds of $143,581 thousand after offering costs of $6,419 thousand.
Mineralys Therapeutics Reports Sharply Higher Expenses and $200M License Payment in Nine Months Ended September 2026
According to the filing, Mineralys Therapeutics (NASDAQ:MLYS) recorded total operating expenses of $351,467 thousand for the nine months ended September 30, 2026, up from $132,324 thousand for the same period in 2025. Research and development expenses were $268,410 thousand for the nine-month period, compared to $107,607 thousand a year earlier, while general and administrative expenses rose to $83,057 thousand from $24,717 thousand. The company disclosed that an upfront payment of $200,000 thousand under the Fourth Amendment to its License Agreement was a significant non-cash adjustment in reconciling net loss to net cash used in operating activities.
For the three months ended September 30, 2026, total operating expenses were $60,087 thousand, with research and development accounting for $22,668 thousand and general and administrative costs for $37,419 thousand. Interest expense of $3,188 thousand was recorded in the quarter, reflecting the senior secured term loan that was drawn during the 2026 fiscal year. Net cash used in operating activities for the nine months was $115,123 thousand, the company disclosed, compared to $104,528 thousand in the prior-year period.
The accumulated deficit grew to $794,907 thousand as of September 30, 2026, from $457,169 thousand at December 31, 2025. Total stockholders' equity declined to $503,775 thousand from $646,693 thousand over the same period. The company raised additional capital through an at-the-market agreement and a public offering during the nine months, with ATM proceeds net of issuance costs of $20,187 thousand in the first quarter and public offering net proceeds of $143,581 thousand in the second quarter. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company, according to the filing.
What Was Disclosed
Mineralys Therapeutics disclosed its unaudited financial results for the third quarter and nine months ended September 30, 2026, including a nine-month net loss of $337,738 thousand, a $200,000 thousand license agreement upfront payment, a new senior secured term loan, and 88,557,097 shares outstanding as of October 29, 2026.




Please wait processing your request...